Daniel H. Lowenstein (physician)

Daniel H. Lowenstein is an American neurologist who is the Robert B. and Ellinor Aird Professor of Neurology and Executive Vice Chancellor and Provost at the University of California, San Francisco (UCSF). He is known for his work in the field of epilepsy including laboratory-based and clinical research, the clinical care of patients with epilepsy, and advocacy for the needs of patients and family members living with epilepsy. He was the originator of the “Academy of Medical Educators” concept, and is the recipient of teaching awards both at UCSF and nationally. He has served as the Dean for Medical Education at Harvard Medical School, and as President of the American Epilepsy Society. In 2017, he was elected to the National Academy of Medicine in recognition of his contributions to American medicine.[1]

Daniel H. Lowenstein
NationalityAmerican
Alma materHarvard Medical School
AwardsNumerous teaching awards; American Epilepsy Society Basic Research Award (2001)
Scientific career
FieldsNeurology
InstitutionsUniversity of California, San Francisco

Education and academic career

Lowenstein graduated with a B.A. in Mathematics from the University of Colorado (1973), obtained an M.S. degree in Man-Environment Relations from Pennsylvania State University (1978), and received his M.D. from Harvard Medical School in 1983. At the University of California, San Francisco (UCSF), he completed an internship in pediatrics (1983–84), a residency in neurology (1984–87), a two-year fellowship in Stanley Prusiner's Laboratory, and then became a faculty member at UCSF in the Department of Neurology where, in 1998, he was named the Robert B. and Ellinor Aird Professor of Neurology. While at UCSF, he established the UCSF Epilepsy Research Laboratory, and has served as Co-Chair for the Chancellor's Steering Committee on Diversity, and Chair of the “Blue Sky” Curriculum Design Task Force that helped design the new medical school curriculum.[1]

From 2000 to 2003, Lowenstein was Dean for Medical Education at Harvard Medical School (HMS). While there, he oversaw a re-organization of curricular governance, the creation of a new educational technology program, and the establishment of the HMS Academy. In 2003, he returned to UCSF as Division Chief of the UCSF Epilepsy Center, and director of the university's physician-scientist training programs. In February 2015, Chancellor Sam Hawgood tapped the physician-scientist to be second-in-command as the Executive Vice Chancellor and Provost for the university. In this role, Lowenstein leads UCSF's research enterprise and academic program, consisting of four professional schools and a Graduate Division.[1][2]

Lowenstein has been a Member of the Advisory Council of the National Institute of Neurological Disorders and Stroke (NINDS), which helps to define scientific policy at the national level; President of the American Epilepsy Society (2003-2004); Chair of the NINDS Epilepsy Benchmarks Oversight Committee (2000-2014); and Chair of the International League Against Epilepsy Commission on Genetics (2013-2017).[1]

Awards
  • The American Epilepsy Society's 2001 Basic Research Award, an honor given each year to the foremost basic science investigator whose research "contributes importantly to understanding and conquering epilepsy."
  • The American Epilepsy Society 2012 Lennox Award, given to "a clinician-scientist who is felt to be among the most outstanding investigators in the field of epilepsy research."
  • The International League Against Epilepsy 2013 Ambassador Award "in recognition of outstanding international contributions to the cause of epilepsy."
  • The American Neurological Association 2013 Raymond D. Adams Lectureship
  • The American Academy of Neurology 2015 N. Houston Merritt Lectureship[1]

His national teaching awards include:

Lowenstein has also advocated for cultural diversity issues at UCSF, for which he received the 1998 Black Student Health Association's Faculty Award, the 1998 UCSF Dr. Martin Luther King, Jr. Award, and the 2006 Holly Smith Award for Exceptional Service to the UCSF School of Medicine. In 2009, he received the Chancellor's Award for Public Service in recognition of his creation and leadership of the Iraq Action Group which sponsored numerous programs to educate the Bay Area community about the health consequences of the Iraq War.

In 2015 Lowenstein received the Chancellor”s Diversity Award for Disability Service as result of his efforts to remove the stigma associated with mental illness among health professions students.

In 2017, Lowenstein was elected to the National Academy of Medicine in recognition of his contributions to epilepsy research, medical education and leadership in academic medicine.

Research

Lowenstein's clinical and research interests include the genetic factors thought to underlie many forms of epilepsies (idiopathic epilepsies) and the management and treatment of patients with status epilepticus (unusually prolonged seizures).[1]

His laboratory studies (carried out from 1989 to 2002) have addressed the fundamental mechanisms of neuronal network remodeling that occur during epileptogenesis, the process in which a normal network transforms into a hyperexcitable network capable of producing or relaying seizure activity. The main efforts of his research group focused on the various forms of cellular reorganization that are observed in humans with temporal lobe epilepsy, and the parallels between reorganization in the adult nervous system and normal developmental processes. Important findings by his team included the observation of selective neuronal loss in the setting of traumatic brain injury, the discovery that seizure activity in an adult model of temporal lobe epilepsy causes a marked increase in the birth of hippocampal neurons (with post-doc Jack Parent), and the recognition that numerous molecules responsible for normal development are also expressed in this same brain region in the adult.

In 2002, Lowenstein turned his attention toward questions related to the genetic basis of common forms of human epilepsy. Working with colleagues from throughout the world, he helped create the Epilepsy Phenome/Genome Project (EPGP), an international, multi-institutional, collaborative study that aimed to collect detailed phenotype data on 5,250 subjects with specific forms of epilepsy, with the goal of finding the genetic determinants of their disease through whole exome and whole genome sequencing. EPGP enrolled over 4,000 participants and, at the time, compiled the most extensive and detailed phenotype dataset in the history of epilepsy research. In 2011, Lowenstein and colleagues were successful in receiving funding for a new NINDS Epilepsy Center Without Walls, the “Epi4K: Gene Discovery in 4,000 Epilepsy Genomes” which had as one of its goals the analysis of the EPGP cohorts.

The first major findings of the collaborative effort between EPGP and Epi4K, which demonstrated the role of de novo mutations as the cause of many patients with epileptic encephalopathy, appeared in a 2013 issue of Nature. Numerous findings have since been published based on the combined work of EPGP and Epi4K, including a paper in Lancet Neurology describing the role of ultra-rare variants in the common epilepsies. In addition, Lowenstein has helped oversee the phenotyping efforts of the International League Against Epilepsy (ILAE) Consortium on Complex Epilepsies, which completed a meta-analysis of available genotype data on approximately 15,000 epilepsy patients. He is one of the leaders of Epi25, an international effort that has the ultimate goal of completing whole exome and whole genome sequencing on 25,000 patients with epilepsy in collaboration with the Broad Institute and other partner institutions.

Lowenstein's clinical research related to status epilepticus began with retrospective studies of patients admitted to San Francisco General Hospital, as well as a highly cited article suggesting a revision of the definition of status epilepticus. In the 1990s, he was the Principal Investigator of a prospective, multi-centered, NINDS-sponsored clinical trial looking at the potential benefits of active treatment of patients in status epilepticus in the pre-hospital setting. This five-year study, completed in 1999, helped define the optimal therapy for these patients nationally. From 2005 to 2015, Lowenstein served as Co-Principal Investigator and member of the Neurological Emergency Treatment Trials (NETT) Clinical Coordinating Center, which oversaw a network of academic centers and affiliated hospitals in the U.S. carrying out numerous clinical trials related to acute neurological disease. As part of this effort, he was Co-Principal Investigator with Dr. Robert Silbergleit for the Rapid Anticonvulsant Medications Prior to Arrival Trial (RAMPART) study, where he was involved in the design, oversight and implementation of a trial that unambiguously demonstrated the benefits of the administration of intramuscular midazolam in this setting.

RAMPART was selected as the “2013 Clinical Trial of the Year” by the Society for Clinical Trials. Most recently, working with colleagues in the field, Lowenstein helped in the design and implementation of the Established Status Epilepticus Treatment Trial (ESETT), a NINDS-funded, randomized, prospective study of fos-phenytoin, valproate or levetiracetam in the treatment of status epilepticus.

Other accomplishments

While chairing the UCSF “Blue Sky” Curriculum Design Task Force in the late 1990s, Lowenstein is credited for coming up with the idea of “The Academy”, a new approach for supporting the teaching mission of medical schools.The academy movement now involves over 35 institutions across the U.S.[1]

During the first White House-initiated Curing Epilepsy conference held in 2000, Lowenstein suggested that members of the epilepsy research community should attempt to capture the field's current 'state of the art' and define a series of goals for the field that could serve as a research agenda. This led to the adoption by the National Institutes of Neurological Disorders and Stroke (NINDS) of the “Epilepsy Research Benchmarks”, a program that has been led by Lowenstein and used by the NINDS and other funding agencies to help prioritize grant opportunities and demonstrate progress to the legislature and the public at-large.[1]

In April 2013, Lowenstein was selected by the students at UCSF to give “The Last Lecture”, where he was asked to respond to the prompt: “If you had but one lecture to give, what would you say?” Lowenstein's hour-long talk to more than 700 members of the campus community, and described by observers as “alternately inspiring, hilarious, and profoundly moving”, was organized into four threads: adventure, passion, justice, and joy and sorrow.[1]

Publications

Lowenstein has published over 175 scholarly professional journal articles[4] that include:

References
  1. Lowenstein, Daniel. "Executive Vice Chancellor & Provost". UC San Francisco. UCSF.
  2. "Driven by Science, Humanism and Service, Dan Lowenstein Joins UCSF Leadership Team". 29 January 2015.
  3. Alpha Omega Alpha Robert J. Glaser Distinguished Teacher Awards: Previous Award Recipients Archived 2010-06-13 at the Wayback Machine (Accessed 29 May 2010).
  4. 88 items were found in a search on the ISI Web of Science database, refined by: Subject Areas=( NEUROSCIENCES & NEUROLOGY OR BIOCHEMISTRY & MOLECULAR BIOLOGY OR PHARMACOLOGY & PHARMACY OR GENETICS & HEREDITY OR CELL BIOLOGY ) AND Authors=( LOWENSTEIN, DH ) (search conducted 29 May 2010)
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.